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Available online 3 March 2016Lower blood oxygenation level dependent (BOLD) signal changes in response to a visual stimulus in functional
magnetic resonance imaging (fMRI) have been observed in cross-sectional studies of cerebral amyloid
angiopathy (CAA), and are presumed to reﬂect impaired vascular reactivity. We used fMRI to detect a longitudi-
nal change in BOLD responses to a visual stimulus in CAA, and to determine any correlations between these
changes and other established biomarkers of CAA progression. Data were acquired from 22 patients diagnosed
with probable CAA (using the Boston Criteria) and 16 healthy controls at baseline and one year. BOLD data
were generated from the 200 most active voxels of the primary visual cortex during the fMRI visual stimulus
(passively viewing an alternating checkerboard pattern). In general, BOLD amplitudes were lower at one year
compared to baseline in patients with CAA (p= 0.01) but were unchanged in controls (p= 0.18). The longitu-
dinal difference in BOLD amplitudes was signiﬁcantly lower in CAA compared to controls (p b 0.001). White
matter hyperintensity (WMH) volumes and number of cerebral microbleeds, both presumed to reﬂect CAA-
mediated vascular injury, increased over time in CAA (p= 0.007 and p= 0.001, respectively). Longitudinal in-
creases in WMH (rs = 0.04, p = 0.86) or cerebral microbleeds (rs = −0.18, p = 0.45) were not associated
with the longitudinal decrease in BOLD amplitudes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Functional magnetic resonance imaging1. Introduction
Cerebral amyloid angiopathy (CAA) is characterized by the accumu-
lation of beta-amyloid in the media and adventitia of the
leptomeningeal and cortical vasculature (Vinters, 1987). This pathology
causes cerebral arterial bleeding and manifests as lobar intracerebral
hemorrhages (ICH), cerebral microbleeds, subarachnoid hemorrhages,
and superﬁcial siderosis (Knudsen et al., 2001; Charidimou et al.,
2012). CAA is also implicated as a cause of vascular cognitive impair-
ment and dementia (MRC CFAS, 2001), which may be due in part tondent; CAA, cerebral amyloid
ging; FLAIR, ﬂuid attenuated
, susceptibility-weighted imag-
for Healthy Brain Aging, Room
30 Hospital Drive NW, Calgary,
. This is an open access article underischemic lesions caused by subsequent blood ﬂow reduction
(Greenberg et al., 2004; Smith et al., 2012).
Vascular beta-amyloid deposition has been shown to cause thicken-
ing of the vascular walls and loss of smoothmuscle cells, thus impairing
the vascular response to functional hyperemia (Davis-Salinas et al.,
1995). Animal models of CAA have demonstrated impaired vascular re-
activity in response to a vasodilatory challenge in CAA (Shin et al., 2007;
Smith et al., 2008; Park et al., 2014). Cross-sectional functionalmagnetic
resonance (fMRI) studies of CAA in humans have demonstrated delayed
time-to-peak and reduced amplitude of the blood oxygenation level de-
pendent (BOLD) responses to a visual stimulus (Dumas et al., 2012; Peca
et al., 2013) even though clinical tests of visual function and visual
evoked potentials were normal. Altered BOLD responses are typically
more prominent within the occipital lobe compared to the frontal
lobe, consistent with the preferential deposition of vascular beta-
amyloid in posterior brain regions, a characteristic feature of CAA
(Peca et al., 2013). In addition, the degree of reduction of BOLD response
amplitude was strongly correlated with two markers of CAA-related
brain injury: volume of white matter hyperintensity (WMH) of pre-
sumed vascular origin and the number of cerebral microbleedsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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plitude in response to a visual stimulus may provide a potential in vivo
biomarker of CAA severity.
Animalmodels of CAA show that vascular beta-amyloid accumulates
over time, and is associated with progressive loss of vascular reactivity
(Dubois et al., 2007); however, the timing and rate of cerebral hemody-
namic impairment in patients with CAA is unknown because there are
no published longitudinal studies to date.
The present study is designed to determine if BOLD FMRI can track
the progression of the characteristic vascular reactivity impairment ob-
served in CAA, using a one-year prospective longitudinal study design.
We hypothesized that the BOLD response to a visual stimuluswould de-
crease over one year in CAA, but remain unchanged in healthy similarly-
aged controls. Additionally, we hypothesized that the decrease in BOLD
response in CAA would be signiﬁcantly associated with an increase in
the volume ofWMH of presumed vascular origin and the number of ce-
rebral microbleeds, which are presumed to reﬂect the severity of CAA-
related vascular injury.
2. Methods
2.1. Study population
Study participants included 22 patients with CAA and 16 non-
cognitively impaired, stroke-free, healthy controls recruited as a part
of a prospective longitudinal study. Patients presented with MR evi-
dence of ICH,microbleeds, or superﬁcial siderosis without other evident
cause, consistent with the diagnosis of probable CAA by the validated
Boston criteria (Knudsen et al., 2001; Linn et al., 2010). Speciﬁcally,
the CAA population contained 12 patients that presented with ICH, 3
that presented with headache or cognitive impairment with neuroim-
aging evidence of CAA-related inﬂammation (all of whomwere studied
in a phase of remission without MRI FLAIR evidence of acute vasogenic
edema at the time of study), 5 with cognitive symptoms without de-
mentia, and 2 with transient focal neurological episodes. Three patients
were recruited from a cognitive clinic and nineteenwere recruited from
a stroke prevention clinic. Patients were excluded if they resided in a
nursinghomeor long-term care facility, hadmoderate to severe demen-
tia (deﬁned as a Clinical Dementia Rating (CDR) score N1.0), had abnor-
mal visual acuity (b20/50 Snellen visual acuity), or were not ﬂuent in
English (because English language cognitive testing was part of the
study). Patients with recent symptomatic stroke (b90 days) were also
excluded to avoid any acute effects of ICH. Patients with MRI evidence
of ICH in the occipital polewere excluded if their hemorrhagic lesion ex-
tended into the occipital region of interest used to calculate the BOLD
response amplitudes. Healthy controlswere recruited from the commu-
nity by advertising in a newsletter or poster, and did not have a history
of stroke or dementia as determined by neurologist assessment. Each
participant had a repeat study visit and MR imaging at one year. Sub-
jects provided written consent to participate in the study, which was
approved by our Institutional Review Board.
2.2. Measurements
All imaging was performed using a 3.0 Tesla MR scanner (either GE
Signa VH/i or Discovery 750; GE Healthcare, Waukesha, WI) with a 12-
channel phased-array neurovascular coil. Because of a MR scanner
upgrade, 9 of the 22 patients with CAA and 10 of the 16 control subjects
had their baseline scan on a GE Signa VH/i scanner and their one-year
scan on a GE Discovery 750 scanner, while the remaining patients with
CAA and control subjects had both baseline and one-year scans on the
same GE Discovery 750 scanner. A T2-weighted, two-dimensional ﬂuid
attenuated inversion recovery (FLAIR) sequence was used to measure
the WMH of presumed vascular origin volume (TR/TE/TI = 9000/149/
2250 ms, voxel size 0.9 × 0.9 × 3.5 mm, 39 slices, 3.5 mm slice thickness,
256 × 256matrix size). Susceptibility-weighted imaging (SWI) was usedto detect the number of cerebral microbleeds (TR/TE = 30/20 ms, voxel
size 0.9 × 0.9 × 5mm, 120 slices, 2 mm slice thickness, 256 × 256matrix
size). The entire imaging protocol took approximately 1 h and included
diffusion tensor imaging and arterial spin labeling acquisitions that
were not used in the present study.
All T2*-weighted fMRI scanswere acquired using a gradient-recalled
echo, echo planar imaging (GRE-EPI) sequence (TR/TE = 2000/30 ms,
voxel size 3.75 × 3.75 × 4 mm, 34 slices, 4 mm slice thickness, ﬁeld of
view = 240 × 240 mm). During fMRI scans, participants viewed four
repetitions of 40-second blocks of an 8-Hz contrast-reversing checker-
board visual stimulus followed by40 s of a grey screenwith a centralﬁx-
ation cross.
2.3. Image analysis
All fMRI data were processed using the FMRIB Software Library (FSL
version 5.0.1, Oxford, UK). Following brain extraction (Smith, 2002),
fMRI data were corrected for interleaved slice timing, corrected for mo-
tion using theMCFLIRT tool (Jenkinson et al., 2002), spatially smoothed
(using a 5-mm full-width half maximum Gaussian kernel) and tempo-
rally ﬁltered using a high-pass temporal ﬁlter with a cutoff of 0.01 Hz.
A voxel-by-voxel analysis of each participants fMRI data was then per-
formed using a time-series General Linear Model (GLM) as implement-
ed in the fMRI Expert Analysis Tool (FEAT) (Worsley, 2001) of FSL. The
regressor of interest was a time-series model consisting of the binary
timing of the visual stimulus convolved with a canonical hemodynamic
response function. Estimates of brain activity magnitude in response to
the stimulus were then computed using FEAT and converted to a z-
statistic. The 200 most active voxels (11.3 cm3) exhibiting the greatest
z-statistic within the primary visual cortex were selected as the region
of interest, and the amplitude of the BOLD response (calculated as the
percent change in theMR signal between visual ﬁxation and the check-
erboard stimulus, as estimated using the Featquery tool of FSL) was
compared across imaging sessions for each of the CAA and healthy con-
trol groups using a paired t-test for within-group changes and a two-
sample t-test for between-group differences.
Due to the difference in prevalence of hypertension between the
groups and the variation in MR scanner used between subjects, a
mixed-model linear regression was used to determine whether associ-
ation between CAA and longitudinal BOLD amplitude change over
timewas independent of age, sex, hypertension, orMR scanner. Because
of our modest sample size, we used forward selection to serially enter
and retain covariates signiﬁcantly associated with the outcome,
retaining only signiﬁcant covariates (p b 0.05) or where there was evi-
dence of confounding of the CAA group effect (deﬁned as a 20% shift
in the model beta-coefﬁcient).
Because analyzing the most active voxels, in which the area of acti-
vationmight differ between the baseline and one year scans, couldmin-
imize changes over time, we also performed a secondary analysis where
we analyzed theBOLDamplitude changes in a pre-speciﬁed anatomical-
ly deﬁned region of interest centered on the primary visual cortex,
which is the brain region most heavily affected by vascular amyloid de-
position. The anatomically deﬁned visual cortex V1 region of interest
(Amunts et al., 2000) was extracted from the Juelich Histological Atlas
structures within FSL, and encompassed a 21.7 cm3 volume of the pri-
mary visual cortex in Montreal Neurological Institute (MNI) space
(Fig. 1). The anatomically deﬁned ROI was coregistered into the fMRI
space of each individual and the BOLD amplitude was calculated as an
average of all voxels within the ROI.
In addition, each participant's preprocessed fMRI data set was regis-
tered to the standard MNI brain template to permit a voxel-by-voxel
statistical analysis of the estimates of brain activity for each group across
imaging sessions. This analysis was performed within FEAT using a
mixed effects linear model, and the resulting comparisons between im-
aging sessions were computed as a z-statistic, with clusters of signiﬁ-
cantly activated voxels (z N 2.3) corrected for multiple comparisons at
Fig. 1. Anatomically deﬁned region of interest. The region is a modiﬁed version of the Visual Cortex V1 structure from the Juelich Histological atlas (Amunts et al., 2000). Mean BOLD
response amplitudes were extracted from all voxels within the anatomical region to compare the sampled voxels longitudinally.
Table 1
Characteristics of the study populations.
Characteristics Control (n= 16), n CAA (n= 22), n p-Value
Age in years (mean ± SD) 68.4 ± 5.9 72.6 ± 6.9 0.06
Female 9 7 0.19
Hypertension 1 18 b0.001
Coronary artery disease 1 2 0.99
Atrial ﬁbrillation 0 2 0.50
Hypercholesterolemia 12 8 0.99
Diabetes 0 5 0.06
Smoker 1 2 0.99
Baseline WMH volume (mL) 2.34 (1.71–5.27) 24.8 (10.77–44.01) b0.001
WMH volume change (mL) 0.33 (−0.15–1.09) 1.36 (−0.48–7.37) 0.03
Baseline microbleeds 0 24 (6–54) b0.001
New microbleeds at one year 0 11 b0.001
Number of new microbleeds 0 1 (0−23) b0.001
Values are mean ± standard deviation, median (interquartile range) or number. Signiﬁ-
cance testing by t-test (age), Wilcoxon rank-sum test (WMH and number of new
microbleeds), or Fisher's exact test (categorical variables). WMH volume change deﬁned
as WMH volume at one year subtracted by volume at baseline.
For all statistical tests, a p-value b 0.05 was considered to be signiﬁcant.
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age, http://afni.nimh.nih.gov/afni/doc/manual/AlphaSim). The change
in BOLD response amplitude across imaging sessions were restricted
to those voxels that exhibited a z-statistic N 0 for each imaging session.
This ensured that differences in BOLD response amplitudes across
sessions did not occur spuriously due to sub threshold negative
responses during any one session. This analysis was performed to deter-
minewhether therewere commonbrain regionswithin each group that
exhibited a change in BOLD response amplitude across imaging
sessions.
WMHandmicrobleedswere classiﬁed and reported according to the
standards for reporting vascular changes on neuroimaging (STRIVE)
(Wardlawet al., 2013).WMHvolumewithin the T2-weighted FLAIR im-
ages collected at baseline and one year was determined for each partic-
ipant by a single rater using Quantomo, a custom-designed software
application (Cybertrials Inc; Calgary, AB, Canada). Quantomo software
employs a semi-automated threshold-based seed-growing algorithm
to detect the volume of hyperintense signal by a trained rater (Kosior
et al., 2011). To account for differences in head sizes between subjects,
WMH volumes were normalized to the average intracranial volume of
participants in a population-based study such that reported WMH vol-
ume represented the volume of WMH in a subject with an average in-
tracranial volume (1449 cm3) (Smith et al., 2015). WMH volumes
were measured on baseline and one year FLAIR images to determine
WMH progression over time, blinded to fMRI results.
SWI sequences were independently viewed to determine the num-
ber of cerebral microbleeds by two raters (ES and SB), with the ﬁnal
number determined by consensus. One patients SWI was not collected
at baseline. Raters were blinded to clinical information, time of scan,
and fMRI results. We have previously demonstrated good reliability
for counting microbleeds using this technique (Cheng et al., 2013).
2.4. Statistical analysis
BOLD response amplitudes were normally distributed and were
compared within each group by paired t-test. The absolute difference
betweenBOLD response amplitudes at one year and baselinewere com-
pared between CAA and healthy control groups by two-sample t-test.
G*Power version 3.1.9.2 (Universitat Kiel, Germany) was used to deter-
mine sample sizes for a putative trial of an agent to preserve the BOLD
response amplitude in CAA, assuming the placebo-treated group
would change by −0.34% (standard deviation 0.71%) as observed in
the patients with CAA in our study. These sample size calculations
used two-tailed t-tests for independent means with 80% power and
alpha 0.05. WMH volumes and number of cerebral microbleeds had
right-skewed distributions andwere log transformed to allow for longi-
tudinal comparison by paired t-test. For patients with CAA, the associa-
tions between change in BOLD response amplitude across sessions and
WMH volume and number of cerebral microbleeds was assessed by
computing the Spearman correlation coefﬁcient (rs) using SAS version9.3 (Cary, NC). For all statistical tests, a p-value b 0.05 was considered
as signiﬁcant.
3. Results
3.1. Demographics
Clinical characteristics of each group are described in Table 1.
Patients with CAA were more likely to have hypertension than the
healthy controls (p b 0.001), but had similar distributions of coronary
artery disease, atrial ﬁbrillation, hypercholesterolemia, diabetes
mellitus, and tobacco use.
3.2. BOLD response amplitude
Mean BOLD signal change for CAA and healthy controls at both base-
line and one year, are plotted in Fig. 2. The amplitude of the BOLD
response at baseline and one year are displayed graphically for healthy
controls and patients with CAA (Fig. 3). In healthy control subjects, the
mean BOLD response amplitude did not change between baseline and
one year sessions (Fig. 3A). In patients with CAA, the mean BOLD
response amplitude at one year was signiﬁcantly less than at baseline
(Fig. 3B).
The results of mixed-model linear regression are shown in Table 2.
There was a signiﬁcant decrease in BOLD response amplitude over one
year in patients with CAA, from 1.98% to 1.64% (difference −0.34%,
95% CI−0.97 to−0.14, p= 0.01) but no signiﬁcant change in healthy
controls, from 2.54% to 2.76% (difference +0.21%, 95% CI −0.10 to
+0.53, p = 0.18). The change over time between patients with CAA
and control subjects was also signiﬁcant (p b 0.001).
Fig. 2.Mean BOLD signal change in response to a visual stimulus for healthy controls and patients with CAA. Fig. 2A and B show mean BOLD signal change in healthy controls (A) and
patients with CAA (B) at baseline and one year, in response to viewing four repetitions of 40-second blocks of an 8-Hz contrast-reversing checkerboard visual stimulus followed by
40 s of a grey screen. Fig. 2C and D show mean BOLD signal change averaged across the four stimulus blocks in healthy controls (C) and patients with CAA (D) at baseline and one
year. BOLD signal is expressed as percent change from baseline (deﬁned as 0%). Error bars indicate standard error of the mean.
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ed, serially adding additional covariates for age, sex, hypertension and
scanner effect. In the model controlling for CAA group status, there
was no effect of age (p = 0.15), sex (p = 0.28), hypertension (p =
0.87), or scanner model (p= 0.19) on change in BOLD response ampli-
tude response across sessions.
The longitudinal decrease in BOLD response amplitudes in patients
with CAA remained signiﬁcant in secondary analyses that employed
an anatomically deﬁned ROI including the primary visual cortex (Fig.
1), rather than the 200 most active voxels for extracting BOLD response
amplitudes (1.23% ± 0.56% vs. 1.01% ± 0.51%, p= 0.03).Fig. 3. BOLD response amplitude (expressed as the percentage change in signal between the s
BOLD response amplitude did not change across imaging sessions in controls (2.54 ± 0.58% v
0.87% vs. 1.64 ± 0.77%, p= 0.01). Colored markers denote mean BOLD response amplitude an
linear regression.The results of the whole-brain group analyses are shown in Fig. 4.
The amplitude of the BOLD response signiﬁcantly decreased across im-
aging sessions within the primary visual cortex of patients with CAA.
In a hypothetical early phase randomized controlled trial designed
to provide 80% power to detect differences between a BOLD
amplitude-preserving intervention vs. placebo (expected change in pla-
cebo−0.34% at one year), 110 subjects (total of treatment and placebo
groups) would be needed to demonstrate no change in BOLD response
amplitudes at one year in the treated group (i.e., no change from base-
line in the treated group), 432 subjectswould beneeded to demonstrate
a 50% reduction in loss of BOLD amplitude (i.e., absolute−0.17% changetimulus and ﬁxation) at baseline and one year for control subjects and patients with CAA.
s. 2.75 ± 0.61%, p= 0.18), but decreased across sessions for patients with CAA (1.92 ±
d error bars represent standard deviations. Signiﬁcance was determined by mixed model
Table 2
Mixed model linear regression results.
Baseline One
year
Difference over time (baseline
minus one year)
p-Value for difference from
baseline to one year
p-Value (baseline difference
between CAA and control)
p-Value (difference between CAA and
control in change over time)
CAA 1.98% 1.68% −0.34% 0.01 b0.001 0.01
Control 2.54% 2.76% +0.21% 0.18
The change from baseline to one year was signiﬁcant for CAA (p= 0.01) but not for controls (p= 0.18).
For all statistical tests, a p-value b 0.05 was considered to be signiﬁcant.
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demonstrate a 50% increase in BOLD amplitude (i.e., +0.17% increase
from baseline in the treated group).
3.3. Longitudinal WMH volume and cerebral microbleed count changes
In patients with CAA, WMH volumes signiﬁcantly increased over
time (median 1.36 mL, interquartile range −0.48 to 7.37 mL, p =
0.007) (Fig. 5A). At one year, the median number of new microbleeds
was 1 (interquartile range 0 to 23, p = 0.001) (Fig. 5B). New
microbleedswere seen in 11 of the 21 patients. None of the patients de-
veloped new symptomatic hemorrhages over the course of observation.
3.4. Association between BOLD response changes and WMH and
microbleeds
Longitudinal decrease in BOLD response amplitude in the visual cor-
tex was not correlated with higher baseline WMH volume (rs = 0.17,
p= 0.46), WMH volume change over time (rs= 0.04, p= 0.86), num-
ber of microbleeds at baseline (rs = 0.36, p= 0.11) or number of new
microbleeds (rs=−0.18, p=0.45) (Fig. 6). A post-hoc analysis also re-
vealed that the change in BOLD response amplitude across sessionswas
not signiﬁcantly different between patients with newmicrobleeds (n=
11;−0.42% over one year) and patients without newmicrobleeds (n=
10,−0.23% over one year) (p= 0.56).
4. Discussion
A detectable decrease in BOLD response amplitude over a one-year
period in patientswith probable CAA but not in healthy controls implies
that progressive impairment of vascular reactivity is a distinct feature of
CAA. Our results also conﬁrm previous literature showing that BOLD re-
sponses to visual stimuli do not decrease over one year in older patients
without cerebrovascular disease (Stefanova et al., 2013). The present
study provides the ﬁrst evidence that blood ﬂow responses to visual
stimuli worsen over time in CAA; however, we did not ﬁnd correlations
between baseline or incidentWMH ormicrobleeds and change in BOLD
response amplitude.Fig. 4. Change in BOLD response amplitude across imaging session for patients with CAA. BOLD
Areas of activation were cluster corrected to a signiﬁcance level of p= 0.05.The results presented here are consistent with previous cross-
sectional studies suggesting impaired visual stimulus-driven vascular
reactivity as a novel characteristic of CAA (Dumas et al., 2012; Peca
et al., 2013). Previous studies suggest that lower BOLD response ampli-
tudes in response to a visual stimulus are a result of vascular impair-
ment and not neuronal dysfunction in CAA (Peca et al., 2013). Further,
another study showed reduced blood ﬂow responses to a visual stimu-
lus in patients with CAA compared to healthy controls, despite constant
resting blood ﬂow in both populations (Dumas et al., 2012). These ﬁnd-
ings suggest that decreased BOLD response amplitudes in CAA result
from impaired vascular reactivity rather than lower baseline blood
ﬂow delivery due to decreased neuronal activity or abnormal cerebral
blood supply. While the two previous cross-sectional studies have pro-
vided evidence for impaired vascular reactivity as an important feature
of CAA, the present study is the ﬁrst to detect progression over time. A
previous study showed that vascular reactivity was impaired in a pa-
tient with pre-symptomatic hereditary CAA (Smith et al., 2008); the
present study shows that impaired vascular reactivity does not plateau
in the early stages of the disease and instead progressivelyworsens over
time.
In our primary analysis we deﬁned the region of interest based on
the most active voxels for each scan, analogous to the approach in our
cross-sectional study (Peca et al., 2013). However, because themost ac-
tivated voxels may not overlap completely across imaging sessions due
to progressive disease activity as well as normal physiological variation
(Bennett and Miller, 2010; Raemaekers et al., 2012), we performed a
secondary analysis where we determined the BOLD response in a larger
anatomically deﬁned region, selected independently of voxel activation.
The ﬁndings of our secondary analysiswere concordantwith our prima-
ry analysis method; with both approaches showing reduced BOLD re-
sponse amplitudes at one year compared to baseline in patients with
CAA.
Longitudinal BOLD response amplitude could be a useful biomarker
for early phase trials in CAA; however, more than 100 randomized pa-
tients may be needed to elucidate whether the intervention could pre-
serve the BOLD amplitude response. Further reductions in sample
sizes could be achieved by allowing a longer duration of follow-up or
by implementing repeatedMRImeasurements to more precisely deﬁne
individual trajectories over time.response was signiﬁcantly lower at one year within the primary visual cortex only (blue).
Fig. 5. Progression of white matter hyperintensity (WMH) and microbleeds in patients with CAA. A) WMH volume increased over time (median 1.36 mL, interquartile range−0.48 to
7.37 mL, p= 0.007). B) More microbleeds were found at one year than baseline (median 1, interquartile range 0 to 23, p= 0.001).
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individuals, but volume is much higher in patients with CAA or other
vascular diseases (Holland et al., 2008). WMH is considered a marker
of CAA severity (Greenberg et al., 2014), and WMH progression has
been detected in patients with CAA over a median of 14 months
(Chen et al., 2006). Our results conﬁrm that WMH progression can be
detected in CAA over a short time interval. However, we did not ﬁnd a
correlation between either baseline WMH or WMH progression and
the decrease in BOLD response amplitudes. Similarly, we did not ﬁnd a
correlation between baseline microbleed count, or an increase in
microbleed number, and BOLD response amplitude change. The reason
for the lack of correlations between these CAA markers is unclear. It
could be related to imprecision due to the small study sample size and
short period of follow-up (one year). Alternatively, it could indicate
that although impaired vascular reactivity is a feature of CAA, it is not di-
rectly associated with WMH or microbleeds. It may be that
vasoreactivity changes precede the development of CAA-related vascu-
lar injury, such as WMH of presumed vascular origin and cerebral
microbleeds.
The principal limitation to our study is the small sample size with
only one year of follow-up. Although we were able to detect a signiﬁ-
cant decrease in BOLD response amplitude over time in CAA we had
limited power to detect whether BOLD amplitude signal decreases
were associated with other markers of CAA-related brain injury and
could not look for associationswith clinical hemorrhagic events because
none occurred during the timeframe of this study. Larger studieswill be
needed to investigate the relationship between BOLD response ampli-
tude change over time and clinical events. CAA may present as one of
several different clinical syndromes, including stroke due to intracere-
bral hemorrhage, cognitive impairment or transient focal neurological
episodes. Future, larger studies will be needed to determine whetherFig. 6. Longitudinal relationships between absolute longitudinal difference in BOLD amplitude
BOLD amplitude in the visual cortex was not correlated with WMH volume increase over time
cortex was not correlated with the number of new microbleeds (rs =−0.18, p= 0.45; n= 2BOLD decreases are similar in these different CAA syndromes. Patients
were only reassessed at one year and although a signiﬁcant longitudinal
decrease in BOLD response amplitude was detected, a longer follow-up
with one year intervals could be helpful in determining the time course
of BOLD response changes in CAA, including the identiﬁcation of stages
in CAA severity, and how it can be used to predict brain injury and CAA-
related ICH. BOLD response amplitude was chosen as our primary
outcome; further studies are needed to determine how other features
of the BOLD response (e.g. time to peak) change over time. Finally,
measuring vascular reactivity more directly (for example by using
carbon dioxide inhalation as a vasodilatory stimulus), could yield mea-
surements that correlate better with brain injury in CAA, although such
techniques are more technically challenging than visual stimulus-
related fMRI.
This study extends our knowledge of blood ﬂow regulation distur-
bances in CAA by showing that changes in BOLD response amplitude
to a visual stimulus can be detected over one year, with reduced BOLD
responses at one year in the CAA group but not in similarly-aged con-
trols. By showing that change over time can be detected during a clini-
cally feasible follow-up period of one year, these ﬁndings support the
utility of visual stimulus-related BOLD response amplitude as one of a
growing number of biomarkers in CAA. Because BOLD response ampli-
tude change is a continuously distributed measure of vascular function,
it could potentially be improved in the short termby treatments that re-
store more normal vascular function. This offers a potential advantage
over other biomarkers, such as MRI evidence of microbleeds or WMH,
that represent non-modiﬁable and slowly accruing irreversible struc-
tural changes. Therefore, BOLD fMRI may be a useful surrogate outcome
marker for early phase clinical trials where it would not be feasible to
recruit the large numbers of patients needed to detect outcomes such
as symptomatic recurrent ICH. (Greenberg et al., 2014) The presents and WMH volume or microbleed count progression in CAA. A) Longitudinal decrease in
(rs = 0.04, p= 0.86; n= 22). B) Longitudinal decrease in BOLD amplitude in the visual
1).
467A.R. Switzer et al. / NeuroImage: Clinical 11 (2016) 461–467study shows progressive decreases in BOLD response, suggesting pro-
gressively impaired vascular reactivity, are detectable in CAA; whether
modifying vascular reactivity is possible and beneﬁcial to the patient
awaits the development of effective treatments for CAA, for which
there are currently none. However, a visual fMRI surrogate outcome,
similar to our visual fMRI stimulus, has been incorporated as the princi-
pal surrogate outcome measure in an early phase clinical trial of the
anti-abeta monoclonal antibody ponezumab for treatment of CAA
(clinicaltrials.gov NCT01821118). This trial will provide the ﬁrst evi-
dence for whether CAA-associated vascular dysfunction is potentially
modiﬁable.
5. Conclusions
Reduced BOLD response amplitude was observed at one year com-
pared to baseline in patients with CAA but not in similarly-aged con-
trols. However, we did not ﬁnd an association between the degree of
BOLD response amplitude reduction over time and the progressive in-
crease in WMH of presumed vascular origin or number of cerebral
microbleeds. These ﬁndings support the utility of visual stimulus BOLD
response amplitude as a marker of disease progression in CAA, which
may reﬂect aspects of disease progression independent of WMH or ce-
rebral microbleed progression.
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